Clinical Trials Logo

Shock clinical trials

View clinical trials related to Shock.

Filter by:

NCT ID: NCT04337983 Completed - COVID-19 Clinical Trials

Hemodynamic Characteristics of Patients With SARS-CoV-2

PiCCOVID
Start date: March 13, 2020
Phase:
Study type: Observational

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a public health emergency of international concern. Hospitalized COVID-19-positive patients requiring ICU care is increasing along with the course of epidemic. A large number of these patients developed acute respiratory distress syndrome (ARDS) according to current data. However, the related hemodynamic characteristic has so far been rarely described.

NCT ID: NCT04325035 Active, not recruiting - Cardiogenic Shock Clinical Trials

The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock

SEISMiC
Start date: September 28, 2020
Phase: Phase 2
Study type: Interventional

This is a pilot, multinational, randomized, double-blind, placebo-controlled, 2-part safety and efficacy study. Subjects will consist of patients hospitalized for acute decompensated heart failure with persistent hypotension.

NCT ID: NCT04323709 Completed - Cardiogenic Shock Clinical Trials

Levosimendan for Veno-arterial ECMO Weaning

WEANECMO
Start date: January 1, 2019
Phase:
Study type: Observational

Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a temporary mechanical circulatory support that has been increasingly used over the last decade to restore and maintain adequate end-organ perfusion, with data suggesting improvement in outcome for patients with refractory cardiogenic shock. Nevertheless, VA-ECMO weaning should be questioned every day during patient's support. Indeed, studies have shown that the incidence of severe complications related to ECMO is associated with longer circulatory support duration. Inotropes such as dobutamine are currently used to improve myocardial contractility during VA-ECMO support with the aim to enhance left ventricular ejection, aortic valve opening and to shorten ECMO duration. However, many data suggest an increase in mortality related to predisposition to myocardial ischemia and arrythmias. Levosimendan is a calcium sensitizing inotropic agent with systemic, coronary and pulmonary vasodilatory properties and specific cardioprotective effect without increasing myocardial oxygen consumption. The use of levosimendan in patients undergoing VA-ECMO may therefore be of interest both to reduce the duration of mechanical support and to minimize severe complication with few data suggesting a potential benefit of levosimendan for VA-ECMO weaning and survival in post-cardiotomy low cardiac output syndrome with improvement of endothelial function and hemodynamics. Investigators therefore sought to investigate whether the use of levosimendan improves weaning for patients undergoing VA-ECMO support for refractory cardiogenic shock hospitalized in the surgical intensive care unit (ICU).

NCT ID: NCT04320394 Withdrawn - Septic Shock Clinical Trials

Evaluation of Sepsis-induced Immunosuppression Base on QuantiFERON Monitor® in Septic Shock

MONITOR SEPSIS
Start date: July 1, 2020
Phase: N/A
Study type: Interventional

QuantiFERON Monitor® is an immunological test evaluating the nonspecific cellular response by measuring interferon gamma (IFNγ) secretions after T-cell and natural killer lymphocyte stimulation. This study aims at evaluating sepsis-induced immunosuppression base on QuantiFERON Monitor® in patients presenting to the intensive care unit for septic shock. The sponsor expects to identify sepsis-induced immunodeficiency in patients through a better understanding of cellular and adaptive immune responses.

NCT ID: NCT04312581 Completed - Stroke Clinical Trials

Extracorporeal Shock Wave Therapy on Wrist and Hand Functions in Spastic Chronic Stroke Patients

Start date: March 21, 2020
Phase: N/A
Study type: Interventional

40 chronic stroke patients with upper limb spasticity will randomly divided into two groups. First group will receive 3 sessions of radial extracorporeal shock wave therapy (rESWT) with one week apart without cessation of current physical therapy, while the second group will continue to receive conventional rehabilitative program. Assessment will be done at baseline, 2 weeks after rESWT and 3 months after rESWT using Modified Ashworth Scale, Fugl Meyer Assessment for hand function and wrist control, motricity index for pinch grip and Hmax/ Mmax amplitude ratio of flexor carpi radialis muscle.

NCT ID: NCT04303455 Completed - Shock Clinical Trials

Renin as a Biomarker of Haemodynamic Normalisation

Start date: March 24, 2020
Phase:
Study type: Observational

Study design Observational, single centre, prospective cohort study Planned sample size 100 participants Inclusion criteria The study will evaluate a cohort of participants meeting the following inclusion criteria: 1. admission to the Intensive Care Unit (ICU) after elective and emergency cardiac surgery using cardiopulmonary bypass 2. age 18 years and above 3. arterial, central venous and pulmonary arterial catheters have been inserted as part of routine care Study procedures In addition to routine clinical postoperative data and blood collection, serum renin levels will be analysed on admission, 6 and 24 hours after admission to ICU Study duration 6 months

NCT ID: NCT04302584 Completed - Acute Kidney Injury Clinical Trials

Norepinephrine / Vasopressin Combination for Resuscitation in Septic Shock

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

Although norepinephrine is commonly used and is the recommended agent for the treatment of hypotension in volume-resuscitated hyperdynamic septic shock, Low doses of vasopressin may be added to norepinephrine to maintain arterial blood pressure in refractory septic shock and to decrease exposure to norepinephrine. The aim of the work is to compare the effect of norepinephrine alone and Norepinephrine/vasopressin combination on hemodynamics and tissue perfusion in septic shock patients.

NCT ID: NCT04295993 Not yet recruiting - Septic Shock Clinical Trials

Methylene Blue and Microcirculation in Septic Shock

Start date: March 10, 2020
Phase: Phase 3
Study type: Interventional

This trial aims to identify the effects of methylene blue infusion on the the micro-circulation in patients with septic shock. The investigators will evaluate various indices of micro-circulation such as: microvascular flow index, the flow heterogeneity index, the total vessel density, the perfused vessel density, and the proportion of perfused vessels.

NCT ID: NCT04295252 Recruiting - Cardiogenic Shock Clinical Trials

Altshock-2 REGISTRY

Start date: July 1, 2020
Phase:
Study type: Observational [Patient Registry]

The study will provide data on profile, management, outcome, and evolution over time of cardiogenic shock patients admitted to the Intensive Coronary Care Units

NCT ID: NCT04290767 Recruiting - Shock Clinical Trials

Brain Ultrasound With Contrast Microbubbles Injection in Shock Status

Start date: March 6, 2019
Phase: N/A
Study type: Interventional

Alterations in the brain microcirculation may be involved in patients with shock. For a three-day period, we investigate the brain microcirculation using contrast-enhanced ultrasound with microbubble injection in patients with septic and non-septic shock.Ultrasound examination is performed daily to estimate global cerebral blood flow, and to evaluate the brain microcirculation, using variables of the time-intensity brain perfusion curve, after sulphur hexafluoride microbubble Sonovue injection.